Bank Julius Baer & Co. Ltd, Zurich Genenta Science S.P.A. Call Options Transaction History
Bank Julius Baer & Co. Ltd, Zurich
- $25.6 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GNTA
# of Institutions
5Shares Held
248KCall Options Held
0Put Options Held
0-
Al Ti Global, Inc. New York, NY200KShares$999,4370.02% of portfolio
-
Algebris (Uk) LTD London, X045KShares$224,5500.09% of portfolio
-
Ubs Group Ag1.86KShares$9,2910.0% of portfolio
-
Morgan Stanley New York, NY500Shares$2,4950.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$00.0% of portfolio
About Genenta Science S.p.A.
- Ticker GNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,216,900
- Market Cap $90.9M
- Description
- Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated...